The Datar Cancer Genetics Medical Center in Maharashtra, India, has introduced an artificial intelligence platform called the Exacta AI, which offers the most optimized treatment options for cancer patients with multi -elevated analytics.
The platform combines molecular, proteumic, genomic, functional and clinical data and proposes personalized therapeutic solutions using artificial intelligence. Also Exacta AI also provides drug interactions, toxicity and contraindications for a wide range of therapies; Such as antibody combined drugs (ADCS), the inhibitors of immune control stations (CPIS), targeted therapies, hormone therapy, chemotherapy and recovered drugs.
The system can offer up to 10 evidence -based drug compounds for oncologists and molecular tumors (MTBS).
“This approach based on artificial intelligence offers an integrated and evidence -based set of treatment options that can customize cancer treatment,” says Dr. Swanti Lima, director of the Sir Hn Relision Foundation Hospital. To transform it. “
Also, Dr. Dar Dary Patiel, chief executive of World Strategy and Medical Affairs at DCG, points to the platform’s capability to process a huge volume of clinical and molecular data, saying: “When standard treatments are not responsive, physicians must have a large volume of data. Check out and make critical decisions in the shortest possible time. “Exacta AI makes this challenge an opportunity to provide personalized therapies.”
This system based on artificial intelligence also improves the workflow of molecular tumor (MTB) and structured analysis provides physicians with evidence -based treatment options.
The Exacta AI platform offered at least seven treatment options for each patient in a review study of four patients with drug -resistant cancers in hard organs (such as lungs, liver or breast). In contrast, the usual molecular survey methods offered only two options for 2 % of patients.
Dr. Vinnite Data, chief executive of the World Strategy and Business Development in DCG, described the technology as a virtual multidisciplinary team that processs data in minutes, while the process takes several days in traditional methods.
The Exacta AI is now available for medical centers and hospitals and comes with training, integration and continuous support.
“This technology provides an unprecedented level and can protect them from being exposed to ineffective treatments,” says Dr. Andy Gaya, an oncology expert at The Cromwell London Hospital.
The 4basecare startup, backed by Infosys, has also provided a similar approach to treat cancer patients in India.
Hitash Gousami, a co -founder and CEO of 4basecare, explained that today the lung cancer patients are divided into different groups in steps 1 and 2 to 2, each group needs its own treatment. A treatment that is effective for one group may not be effective for the other group and even cause side effects.
This shows that the future of cancer treatment will move to fully personalized treatments, instead of standard and uniform methods for all patients.
Latest Passing over countries : Spain | Dominica | United Arab Emirates
RCO NEWS
